PTSD

DotCom Therapy and Goodside Health Collaborate to Address the Shortage of Mental Health Resources in Schools

Monday, September 27, 2021 - 2:00pm

Through this partnership, DotCom Therapy is providing pediatric teletherapy services and resources to extend Goodside Healths current in-school telemedicine service offerings that primarily focus on physical health.

Key Points: 
  • Through this partnership, DotCom Therapy is providing pediatric teletherapy services and resources to extend Goodside Healths current in-school telemedicine service offerings that primarily focus on physical health.
  • DotCom Therapys web-based teletherapy application, Zesh, helps address this shortage by providing counseling services to Goodside Health patients directly in their school nurses office.
  • Together, we provide increased access for students to address their mental health concerns with pediatric mental health resources from qualified professionals around the country.
  • Goodside Health partners with districts to bring on-demand telehealth and mental health services to schools at no cost to the district.

BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders

Monday, September 27, 2021 - 1:00pm

BetterLife is developing one of the new compositions of 2-bromo-LSD (TD-0148A) covered by its newly filed provisional patent application.

Key Points: 
  • BetterLife is developing one of the new compositions of 2-bromo-LSD (TD-0148A) covered by its newly filed provisional patent application.
  • BetterLife is already in advanced stages of GMP manufacturing TD-0148A and initiated the necessary preclinical IND-enabling studies for TD-0148A.
  • We are excited to be developing and bringing to market treatments addressing cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders.
  • BetterLifes pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency and insomnia.

Nikean Foundation announces $5 million gift to create a Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN)

Monday, September 27, 2021 - 11:15am

Toronto, Ontario, Sept. 27, 2021 (GLOBE NEWSWIRE) -- The Nikean Foundation (Nikean), a Toronto-based charitable foundation committed to the promotion of research and education in support of the beneficial use of psychedelic medicines, has announced a $5 million transformational gift today in support of psychedelic psychotherapy at the University Health Network (UHN).

Key Points: 
  • Toronto, Ontario, Sept. 27, 2021 (GLOBE NEWSWIRE) -- The Nikean Foundation (Nikean), a Toronto-based charitable foundation committed to the promotion of research and education in support of the beneficial use of psychedelic medicines, has announced a $5 million transformational gift today in support of psychedelic psychotherapy at the University Health Network (UHN).
  • The gift is the largest ever donation in support of psychedelic science and research in Canada.
  • By accepting this gift, UHN is sending a powerful message that Canada is serious about psychedelic research and tackling the existential mental health crisis affecting the masses.
  • Affiliated with UHNs Centre for Mental Health, the new Nikean Psychedelic Psychotherapy Research Centre will anchor Canadas thriving psychedelic innovation and academic research hub, leading to revolutionary advances in how Canada treats mental illness and end-of-life distress.

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Monday, September 27, 2021 - 8:30am

As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.

Key Points: 
  • As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.
  • "We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind.
  • "I'm very excited to lead our team and launch a clinical studyfor the treatment of female Hypoactive Sexual Desire Disorder," said Dr. Joel Raskin, Chief Medical Officer, MINDCURE.
  • This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder."

PsychoGenics Chief Innovation Officer Honored for Scientific Excellence

Thursday, September 23, 2021 - 5:31pm

PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of the Year Award ( GMiS 2021 Award Winners ).

Key Points: 
  • PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of the Year Award ( GMiS 2021 Award Winners ).
  • She joined PsychoGenics in 1999 where she developed preclinical tests for cognition, neurodegeneration, autism, among others.
  • She conceived of the SmartCube discovery system and worked on the development of PsychoGenics AI technologies.
  • PsychoGenics Inc. and its discovery arm PGI Drug Discovery LLC (collectively known as PsychoGenics) have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping.

Eaze Launches Statewide Program To Bring Free Medical Cannabis to Low-Income Patients

Thursday, September 23, 2021 - 2:00pm

Eaze Compassion bridges the “last mile” between low-income patients and the products they need to survive and thrive. Utilizing Eaze’s statewide network of brands and delivery drivers, Eaze Compassion aggregates donated products and then -- working with leading compassion organizations including Weed For Warriors, Operation Evac, This Is Jane Project and Brownie Mary Democratic Club -- identifies patients shut out from the legal market by high taxes or residency in the 70% of California jurisdictions where legal cannabis commerce is banned.

Key Points: 
  • Eaze , the nations largest cannabis delivery marketplace, today celebrated the launch of Eaze Compassion, a statewide program to restore medical cannabis access to patients left behind by Californias cannabis laws.
  • Eligibility is determined and verified by Eaze Compassions partner organizations based on criteria including income, medical diagnosis, and need.
  • Interested patients can contact Operation Evac , Weed for Warriors , This is Jane Project , Bay Area Americans for Safe Access and Dear Cannabis for information on Eaze Compassion eligibility.
  • Under Prop 215, medical providers could donate cannabis free of charge to low income patients.

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Wednesday, September 22, 2021 - 12:30pm

In addition, the Company is pleased to report positive preclinical data supporting the continued development of MYCO-003.

Key Points: 
  • In addition, the Company is pleased to report positive preclinical data supporting the continued development of MYCO-003.
  • This patent pending formulation has the potential to further reduce patient anxiety as compared to pure psilocybin, when used in therapy or medical practice.
  • Mydecine believes these properties will be synergistic and particularly important for the effective treatment of patients with severe PTSD and extreme anxiety disorders.
  • Mydecine Innovations Group is headquartered in Denver, Colorado, USA with international offices in Leiden, Netherlands.

Bright Minds Biosciences Provides Scientific Update

Wednesday, September 22, 2021 - 12:00pm

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today provided an update of significant scientific developments.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today provided an update of significant scientific developments.
  • Over the past few months, we have dramatically improved BMBs competitive position with our therapeutic categories, as well as our broader capital markets strategy, stated Ian McDonald, CEO of Bright Minds.
  • This compound and its analogues were first invented by Bright Minds Chief Scientific Officer, Dr. Alan Kozikowski and Dr. Jianjun Cheng at the University of Illinois in Chicago.
  • Bright Minds Biosciences Inc. (the Company) has engagedIn-Site Communications Inc. (In-Site), previous service provider of the Company, for a 12-month term ending on March 30, 2022.

CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A

Wednesday, September 22, 2021 - 6:00am

The GABAB receptor has previously been shown to be instrumental in controlling the overexpression of Peripheral Myelin Protein-22 (PMP22) in a rat model of CMT1A.

Key Points: 
  • The GABAB receptor has previously been shown to be instrumental in controlling the overexpression of Peripheral Myelin Protein-22 (PMP22) in a rat model of CMT1A.
  • Strategic alliances with pharmaceutical partners like Addex Therapeutics support drug development efforts to deliver therapies to CMT patients.
  • We are excited to establish this partnership with Addex Therapeutics as they work to advance their PAMs to treat CMT1A, said CMTAs CEO Amy Gray.
  • Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsons disease and mGlu3 PAM for neurodegenerative disorders.

Ketamine One Signs LOI with Veteran Services USA to Open Therapy Center

Tuesday, September 21, 2021 - 12:00pm

Located in the former MetroSouth Medical Center, the Blue Island Therapy Center is being planned to be part of a larger medical complex.

Key Points: 
  • Located in the former MetroSouth Medical Center, the Blue Island Therapy Center is being planned to be part of a larger medical complex.
  • Pursuant to the LOI, Ketamine One will provide ketamine assisted therapy in other properties in the Veteran Services USA portfolio.
  • The Company will be working with Veteran Services USA to identify further clinic locations for Ketamine One to develop within the growing network of Veteran Services USA properties.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.